Calamos Wealth Management LLC Buys 53,252 Shares of Boston Scientific Corporation $BSX

Calamos Wealth Management LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 52.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 155,038 shares of the medical equipment provider’s stock after buying an additional 53,252 shares during the period. Calamos Wealth Management LLC’s holdings in Boston Scientific were worth $15,136,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 3,932 shares during the period. State Street Corp raised its position in shares of Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its stake in shares of Boston Scientific by 75.3% in the second quarter. Bank Pictet & Cie Europe AG now owns 164,654 shares of the medical equipment provider’s stock valued at $17,685,000 after buying an additional 70,753 shares during the period. MRA Advisory Group bought a new stake in shares of Boston Scientific in the second quarter valued at approximately $273,000. Finally, Bank of New Hampshire grew its position in Boston Scientific by 552.0% during the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after buying an additional 16,699 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 93,095 shares of company stock valued at $9,305,450 in the last 90 days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Up 0.2%

BSX opened at $95.98 on Wednesday. The company has a market cap of $142.28 billion, a P/E ratio of 51.32, a PEG ratio of 1.93 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The company’s 50 day moving average is $98.36 and its 200-day moving average is $101.05. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Wells Fargo & Company lifted their price objective on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. UBS Group reiterated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Robert W. Baird increased their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $124.85.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.